The Russian Direct Investment Fund, promoters of the Sputnik V COVID-19 vaccine candidate, has entered into a deal with Hyderabad-based Hetero Biopharma, to manufacture over 100 million doses annually. The vaccine, announced earlier this week by Russia’s sovereign wealth fund, claimed an “interim efficacy”, via press release, of 91.4%, from its ongoing phase-3 trials. “We are delighted to announce the …
Russian Direct Investment Fund and Indian pharma company Hetero, have agreed to produce in India over 100 million doses per year of Sputnik V covid vaccine in India, Russia's sovereign wealth fund said. RDIF on November 24 had announced positive results obtained during the second interim data analysis of the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia …
The Russian Direct Investment Fund, Russia's sovereign wealth fund, and Hetero, one of India's leading generic pharmaceutical companies have agreed to produce in India over 100 million doses per year of the Sputnik V vaccine against the novel coronavirus infection. Hetero and the Russian Direct Investment Fund, which has been backing the vaccine and marketing it globally, plan to start …
